Perrigo Company plc (NYSE: PRGO) has received final FDA approval for the over-the-counter use of Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg). This marks the company’s first Rx-to-OTC switch, set to enhance its product offerings and strengthen its market presence. Perrigo plans to launch Nasonex® later this year, aiming to provide consumers with quality self-care options. This approval underscores Perrigo's commitment to innovation in self-care products, potentially increasing revenue through expanded market access.
Perrigo Company plc (NYSE; TASE: PRGO) is set to release its fourth quarter and fiscal year 2021 financial results on March 1, 2022, at 8:30 A.M. (EST). A conference call will follow, accessible via webcast on the Perrigo investor relations website. The company is known for its wide range of OTC health and wellness solutions, leading as a store brand OTC player in the U.S. and a top contender in Europe with over 200 branded products across 28 countries. Investors should stay tuned for updates reflecting the company's financial performance and strategic direction.
Perrigo Company plc (NYSE: PRGO) reported its third quarter fiscal 2021 results, revealing net sales of $1.04 billion, a 4.0% increase year-over-year. Organic growth was 2.6% despite challenges including a 5.7 percentage point hit from supply chain disruptions. Adjusted diluted EPS decreased 25.0% to $0.45. The company sees potential in the rebound of its cough/cold business and anticipates adjusted diluted EPS of $2.00 to $2.10 for 2021. Key developments include the completion of the RX business divestiture and acquisition of HRA Pharma.
Perrigo Company plc (NYSE; TASE: PRGO) will announce its third quarter 2021 financial results on November 10, 2021, at 8:30 A.M. (EST). A conference call will follow, available via webcast on the company’s investor relations site. Perrigo is a leading provider of self-care products and OTC health solutions, holding a significant market position with over 9,000 SKUs in the U.S. and ranking among the top 10 OTC companies in Europe.
Perrigo Company plc (NYSE: PRGO) has appointed Jim Dillard as the new EVP and President of Consumer Self-Care Americas (CSCA), effective immediately. Dillard, previously EVP and Chief Scientific Officer, will continue reporting to CEO Murray Kessler. The company has completed its transformation to focus on consumer self-care and resolved an Irish tax uncertainty. Kessler emphasized the importance of profitable growth, while Dillard expressed enthusiasm for leveraging innovation and improving margins. Rich Sorota has mutually separated from the company.
Perrigo Company has settled a significant tax dispute with the Irish Revenue Commissioners regarding an amended income tax assessment. Initially claiming €1.6 billion, the tax liability was reduced to €297 million, which the company will pay, resulting in a net payment of €266.1 million after tax credits. This settlement eliminates a major source of uncertainty for Perrigo, allowing it to refocus on its consumer self-care strategy. Additionally, Perrigo received €355 million related to a previous arbitration award, bolstering its financial position.
Perrigo Company plc (NYSE: PRGO) announced that its President and CEO, Murray S. Kessler, along with CFO Ray Silcock, will participate in investor meetings at the Barclays Global Consumer Staples Conference on September 9, 2021. No formal presentation will be made. As a leader in providing affordable self-care products, Perrigo is the top store brand OTC player in the U.S. and ranks among the top 10 OTC companies in Europe. The company's focus on consumer health solutions positions it well within the competitive landscape.
Perrigo Company plc (NYSE: PRGO) reported a 3.4% increase in net sales for Q2 2021, totaling $981 million, driven by growth across most businesses, despite a weak cough/cold season. However, adjusted diluted EPS fell 15.3% to $0.50 due to higher input costs and reinstated marketing expenditures. The company reaffirmed its 2021 sales guidance, anticipating organic growth of 3%, although EPS expectations were adjusted to the lower end of $2.50 to $2.70 as inflationary pressures persist. Despite challenges, management expresses optimism for future sales recovery and growth opportunities.
Perrigo Company plc (NYSE: PRGO) has declared a quarterly dividend of $0.24 per share, scheduled for payment on September 21, 2021. Shareholders of record as of September 3, 2021 will receive this dividend. The company is noted for providing quality, affordable self-care products and is a leader in the U.S. over-the-counter market, offering more than 9,000 SKUs. The announcement highlights Perrigo's commitment to shareholder returns while emphasizing its strong position in the OTC health market.
Perrigo Company plc (NYSE; TASE: PRGO) is set to disclose its second quarter 2021 financial results on August 11, 2021, at 8:00 A.M. (EDT). The results will be followed by a conference call available via webcast on the investor relations section of their website. Perrigo is a leading provider of affordable OTC health and wellness products, holding a significant market position as the largest store brand OTC player in the U.S. and a Top 10 OTC company in Europe.